Publication | Closed Access

Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide®) in controlled ovarian stimulation for assisted reproduction

Hormonal ContraceptiveUrologyFertilitySignificant ReductionReproductive HealthLhrh Antagonist CetrorelixGynecologyOvarian Hyperstimulation SyndromeReproductive MedicinePublic HealthEndocrinologyMedicineOvarian HormoneOvarian Cancer